Injectable Drug Delivery: A 2-Day Seminar Presented by Experts (London, UK - March 18-19, 2020)

News provided by

Jan 27, 2020, 18:15 ET

DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The "Injectable Drug Delivery" conference has been added to ResearchAndMarkets.com's offering.

This seminar has been designed to provide all those working in the industry with the latest information on the next generation of injectable drugs and devices and an update on recent trends, technologies and applications. It will also be a great opportunity to meet industry leaders, as well as like-minded professionals, and share common experience and best practice.

Attending this two-day seminar, presented by experts in the field, will:

Give you a valuable update on the advances in injection technology and drug delivery
Present you with up-to-date information on the latest market trends and opportunities for your organisation
Provide you with an opportunity to develop significant business partnerships

Injectable drug delivery is considered to be one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, and recent developments have improved the patient experience.

The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.

Agenda

Programme Day One

Devices, technology, and latest trends

Latest developments for injectable drug delivery solutions

Market overview and trends
How can a science-driven CDMO help to accelerate developments for biologics? - Case study
Dr Thomas Schoenknecht

Recent advances in large-volume injection

Large-volume autoinjectors
Patch injectors
Latest usability insights into autoinjector and patch injector systems
Ian Thompson

Discussion session

Developments in technology with injectables - digitalisation and smart technology

Internet of me' - connected drug delivery advances
Sustainable patient engagement for better outcomes
Market forces and business drivers
Neil Williams

Digital design in the development of injectable systems

Hardware and software solutions
Integration into the connected ecosystem
Device management trends
Markus Bauss

Discussion session

Case study: Connected needle-free technology

Adherence to treatment in injectable therapies for chronic disease is very low
Opportunities with a new form of drug delivery that is needle-free
Transforming the perception and approachability of therapies based on injectable biologics
Next-gen needle-free drug delivery platform that is computer-controlled - Supporting patient needs
Clinical and market studies - results and findings
Patrick Anquetil

Patient considerations and design processes

Assessing injection site pain

Understanding how to measure pain and tolerability during injection and how to interpret the results
Summary of recent clinical investigations
Impact on the design and selection of drug delivery devices
Chris Muenzer

Discussion session

Betwixt and between - managing the interface between PFS and autoinjector

Understanding the physical interface between PFS and autoinjector
A framework for ensuring compatibility across the interface
Working together in harmony - the organisational interface between pharma, syringe manufacturer and device developer
Dr Jeffrey Philippson

Interactive panel discussion: Next-generation innovations in drug delivery
Moderator: Dr Gregory Berman
Panellists: Ian Thompson, Neil Williams, Markus Bauss, Dr Thomas Schoenknecht

Drinks reception

Programme Day Two

Regulatory update and human factors

The EU regulatory framework for injectable delivery systems

Deciding on your regulatory strategy
Implications of the Medical Device Regulation (EU) 2017/74 and Article 117 for drug delivery systems
Classification - the importance of getting it right from the start
Combination products - drug/device, device/drug?
Essential considerations for injectable medicinal products
Brexit implications
Dr David Jefferys

Human factors validation - when is usability testing not required?

Overview of regulatory guidelines covering human factors for combination products - Considerations for determining if a study will be required
Utilising comparative analyses
Approaches to compiling supporting evidence
Lee Wood

Discussion session

Sustainability - its impact on self-care drug delivery

The circular economy
Sustainability and the pharma industry
Gregor Anderson

Packaging and quality

Extractables and leachables (E&L) in injectable drug products

The ongoing evolution of thresholds for control of E&L in drug products
Raphael Nudelman

Discussion session

Pre-filled syringes in a nutshell

The components
The building blocks
Potential options
Lure-tip syringes, dual-chamber pre-filled syringes and staked-in needles
How everything comes together
Dr Andreas Rothmund

The relationship between the ICH guidelines for impurities and E&L thresholds

ICH guidelines for impurities and non-mutagenic impurities
Principles from the ICH guidelines for impurities that can be used for the risk assessment of E&L in drug products
Raphael Nudelman

Interactive panel discussion: The future with smart injection devices
Moderator: Dr Gregory Berman
Panellists: Ian Thompson and Dr Thomas Schoenknecht

Chair's closing remarks

For more information about this conference visit https://www.researchandmarkets.com/r/umvzr6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets